Explanatory Note
This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D filed on
October 5, 2020 (as so amended, the “Schedule 13D”) by the Reporting Persons (as defined below), relating to the shares of common stock, par value $0.001 per share (“Common Stock”), of Digimarc Corporation (the
“Issuer” or the “Company”). Each Item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any
of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meaning given to such terms in the Schedule 13D.
This statement on Schedule 13D is being filed by the following persons (each a “Reporting Person” and together the “Reporting
Persons”):
|
|
i.
|
TCM Strategic Partners L.P., a Delaware limited partnership (“TCM Partners”);
|
|
|
ii.
|
TCM Strategic GP LLC, a Delaware limited liability corporation (“TCM GP”), which is the general
partner of TCM Partners; and
|
|
|
iii.
|
Riley McCormack, a citizen of the United States of America and the sole manager of TCM GP
(“Mr. McCormack”).
|
|
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of the Schedule 13D is hereby amended and supplemented by the following:
On December 10, 2020, at a Special Meeting of Shareholders of the Issuer, the shareholders of the Issuer approved, for purposes of
complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of shares of Common Stock upon the conversion of the 16,970 shares of Series B Convertible Preferred Stock, par value $0.001 per share, plus accrued but unpaid dividends, held by
TCM Partners (the “Series B Shares”). As a result of such approval, on December 11, 2020, the Series B Shares automatically converted into 1,198,161 fully paid and non-assessable shares of
Common Stock at a conversion price equal to $14.37 per share. In addition, Mr. McCormack received a grant of 6,546 shares of restricted Common Stock upon his election as a member of the Issuer’s Board of Directors on October 27, 2020
that will vest with respect to 1/3 of the shares on each of the first three anniversaries of the date of grant.
|
Item 5.
|
Interest in Securities of the Issuer
|
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:
(a, b) As of the date hereof, each of TCM Partners and TCM GP may be deemed to beneficially own 3,740,240 shares of Common Stock directly
owned by TCM Partners as the holder of record, representing approximately 22.6% of the shares of Common Stock outstanding, and Mr. McCormack may be deemed to beneficially own 3,746,786 shares of Common Stock, representing approximately 22.7% of
the shares of Common Stock outstanding, calculated based on 15,315,663 shares of Common Stock outstanding as of October 23, 2020, as set forth in the Company’s Quarterly Report on Form 10-Q,
plus the 1,198,161 shares of Common Stock issued on conversion of the Series B Shares and the 6,546 shares of restricted Common Stock issued to Mr. McCormack, for a total of 16,520,370 shares of Common Stock outstanding.
(c) The responses to Items 3 and 4 of this Schedule 13D are incorporated by reference herein. Other than as set forth herein, no
transactions in the Company’s securities have been effected by the Reporting Persons during the past 60 days.
(d) To the knowledge
of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by the Schedule 13D.
(e) Not applicable.